A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of FXS5626 Tablets in Patients With Active Non-infectious Uveitis

The purpose of this study is to find out the efficacy and safety of oral FXS5626 in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

Study Overview

• Status: Recruiting
• Conditions: Active Non-anterior, Non-infectious Uveitis
• Intervention / Treatment: Other: FXS5626 tablet; Other: Placebo

Detailed Description

This study is a multicenter, randomized, double-blind, placebo-controlled study conducted in china, aimed at evaluating the efficacy, safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of FXS5626 administered twice daily for 24 weeks in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis(NIU).

This study plans to enroll 40 patients with active non-anterior NIU. Patients who sign the informed consent form will be screened according to the enrollment criteria, and randomly allocated into 3 groups in a 2:1:1 ratio. Participants in groups 1 and 2 will receive different doses of FXS5626. Participants in group 3 will receive placebo.

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Yang; Phone Number: +86-23-89011876; Email: Peizengyang@126.com
• Study Contact Backup: Name: Ye; Phone Number: +86-23-89011876; Email: 155322188@qq.com

Study Locations

• China
  • Chongqing Municipality
    • Chongqing, Chongqing Municipality, China
      • Recruiting
      • EC of the First Affiliated Hospital of Chongqing Medical University
      • Contact: Yan; Phone Number: +86-23-89011876; Email: cyyy_ll@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Participants must be capable of understanding the trial procedures, voluntarily agree to participate, communicate effectively with the investigators, comply with all study requirements throughout the trial, and provide written Informed consent Form (ICF);
2. At screening visit, male or female paticipants aged 18-70 years (inclusive) ;
3. At screening visit, Body mass index (BMI) between 18 and 30 kg/m² (inclusive), with a body weight of ≥50 kg for males and ≥45 kg for females;
4. At screening, at least one eye was diagnosed with active non-infectious uveitis by the investigator, including non-infectious intermediate uveitis, posterior uveitis, or panuveitis;
5. Subject must have active disease at the screening and baseline visit, as defined by the presence of at least 1 of the following parameters in at least one eye despite at least 2 weeks of maintenance therapy with oral prednisone ≥ 10 mg/day to ≤ 60 mg/day (or oral corticosteroid equivalent):

1) Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion 2) ≥ 2+ anterior chamber cells (Standardization of Uveitis Nomenclature [SUN] criteria) 3) ≥ 2+ vitreous haze (National Eye Institute [NEI]/SUN criteria) ; [6] Participants and their partners must have no plans for reproduction, sperm donation, or egg donation from the start of treatment until at least one month after the last dose of the investigational drug, and must voluntarily employ an effective method of contraception as determined by the investigator.

Exclusion Criteria:

1. Participants with isolated anterior uveitis;
2. Participants with macular edema as the sole clinical manifestation of intermediate uveitis, posterior uveitis, or panuveitis;
3. Participants with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to Tuberculosis (TB), cytomegalovirus (CMV), Lyme disease, toxoplasmosis, Human T-Lymphotropic Virus Type 1 (HTLV-1), Whipple's disease and herpes simplex virus (HSV);
4. Participants with Histoplasmosis Syndrome (HS);
5. Participants with ocular masquerade syndrome, including but not limited to the following causes: trauma, lymphoma, ocular malignant tumor, or surgery;
6. Participants with serpiginous choroidopathy;
7. Participants with corneal or lens opacity that precludes visualization of the fundus in either eye or that likely requires cataract surgery during the duration of the trial;
8. Participants with severe vitreous opacity or other factors that precludes visualization of the fundus in either eye;
9. Participant with uncontrolled glaucoma, intraocular pressure of ≥ 25 mmHg and on ≥ 2 glaucoma medications or evidence of glaucomatous optic nerve injury; The sponsor provides the definitive and complete eligibility criteria in the study protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm1-FXS5626 50 mg group; Participants will receive FXS5626 50 mg twice daily (BID) , for 24 weeks. Pharmaceutical form: Tablets Route of administration: Oral	Other: FXS5626 tablet; Administered twice per day for 24 weeks.
Experimental: Arm2-FXS5626 25 mg group; Participants will receive FXS5626 25 mg twice daily (BID) , for 24 weeks. Pharmaceutical form: Tablets Route of administration: Oral	Other: FXS5626 tablet; Administered twice per day for 24 weeks.
Placebo Comparator: Arm3-Placebo group; Participants will receive placebo twice daily (BID) , for 24 weeks. Pharmaceutical form: Tablets Route of administration: Oral	Other: Placebo; Administered twice per day for 24 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The percentage of patients meeting treatment failure criteria from week 6 to week 24.	24 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Time to Treatment Failure from week 6 to week 24.	24 weeks
At each visit,change in Anterior Chamber (AC) cells grade for each eye from the best state achieved prior to Week 6.	24 weeks
At each visit, change in Vitreous Haze (VH) grade for each eye from the best state achieved prior to Week 6.	24 weeks
At each visit, change in BCVA for each eye from the best state achieved prior to Week 6.	24 weeks
Time to Optical Coherence Tomography (OCT) evidence of macular edema in at least 1 eye from Week 6.	24 weeks
At each visit, change in Central Retinal Thickness (CRT) for each eye from the best state achieved prior to Week 6.	24 weeks

Collaborators and Investigators

• Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): January 29, 2026
• Primary Completion (Estimated): February 28, 2027
• Study Completion (Estimated): December 31, 2027

Study Registration Dates

• First Submitted: March 11, 2026
• First Submitted That Met QC Criteria: April 20, 2026
• First Posted (Actual): April 27, 2026

Study Record Updates

• Last Update Posted (Actual): April 27, 2026
• Last Update Submitted That Met QC Criteria: April 20, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Uveitis; Active; Non-infectious; Non-anterior
• Additional Relevant MeSH Terms: Eye Diseases; Uveal Diseases; Behavior; Uveitis; Motor Activity
• Other Study ID Numbers: FXS5626-CN-PhⅡ-NIU

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No